Trial Profile
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Aug 2019
Price :
$35
*
At a glance
- Drugs Pevonedistat (Primary) ; Azacitidine; Azacitidine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Millennium
- 29 Jul 2019 A population pharmacokinetic analysis was conducted to quantify the impact of patient-specific and concurrent medication factors on pevonedistat pharmacokinetics using pooled data from 6 clinical studies ; results published in the British Journal of Clinical Pharmacology
- 15 Nov 2013 Planned end date changed from 1 Oct 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 08 Oct 2013 Planned end date changed from 1 Sep 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.